Physiomics PLC Strategic Collaboration
03 Janeiro 2019 - 5:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
03 January 2019
3(rd) January 2019
Physiomics plc
("Physiomics") or ("the Company")
Strategic collaboration
Physiomics signs collaboration agreement with UK Medicines
Discovery Catapult
Physiomics plc (AIM: PYC), is pleased to announce that it has
entered into a strategic collaboration with the Medicines Discovery
Catapult ("MDC"). Physiomics will be part of the MDC's "Virtual
R&D" network of advisors and available to provide advice to the
many small biotechnology companies supported by the MDC from its
Alderley Park base. Under the terms of the agreement the MDC will
introduce Physiomics to selected potential clients and in return
will receive a small commission on the value of any service
contracts arising from such introductions.
Physiomics offers a range of services including its proprietary
Virtual Tumour technology to predict the effect of oncology drugs
and improve the success rate of oncology R&D. It works with
companies ranging from start-ups to some of the world's largest
pharmaceutical companies and has experience in a wide range of
treatments, including radiation, DNA repair inhibitors and immune
therapies.
The MDC was established by Innovate UK (part of UK Research
& Innovation) to support the discovery and evaluation of
medicines by providing access to expert technical capabilities,
equipment and other resources required to take new ideas from
concept to reality. Its Virtual R&D group supports UK-based
biotech companies by conducting diligence on their programs as well
as through project management and by connecting them to a variety
of expert consultants and service providers.
Dr Jim Millen, CEO said: "We are delighted to be working with
the MDC; an organisation that plays such a key role in supporting
emerging biotech companies in the UK. We're also excited by the
potential that this new relationship offers to connect Physiomics
to emerging players in the field of oncology."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a solutions provider to the R&D
based pharmaceutical and biotechnology industry with a focus on
oncology. The Company's Virtual Tumour technology uses computer
modelling to predict the effects of cancer drugs and treatments to
improve the success rate of drug discovery and development projects
while reducing time and cost. The predictive capability of Virtual
Tumour has been confirmed by 55 projects, involving over 25 targets
and 60 drugs, and has worked with clients such as Merck KGaA, Merck
& Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAGMGGMKZGGLZM
(END) Dow Jones Newswires
January 03, 2019 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024